SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Uchida, T. Articles by Murate, T. Search for Related Content PubMed PubMed Citation Articles by Uchida, T. Articles by Murate, T. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  RAPID COMMUNICATION Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes Toshiki Uchida, Tomohiro Kinoshita, Hirokazu Nagai, Yohsuke Nakahara, Hidehiko Saito, Tomomitsu Hotta, and Takashi Murate From the First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan; and the Fourth Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan. Previous studies have shown that the cyclin-dependent kinase inhibitor (CDKI) genes p15INK4B and p16INK4A are frequently inactivated by genetic alterations in many malignant tumors and that they are candidate tumor-suppressor genes. Although genetic alterations in these genes may be limited to lymphoid malignancies, it has been reported that their inactivation by aberrant methylation of 5' CpG islands may be involved in various hematologic malignancies. In this study, we investigated the p15INK4B and p16INK4A genes to clarify their roles in the pathogenesis of myelodysplastic syndrome (MDS). Southern blotting analysis showed no gross genetic alterations in either of these genes. However, hypermethylation of the 5' CpG island of the p15INK4B gene occurred frequently in patients with MDS (16/32 [50%]). Interestingly, the p15INK4B gene was frequently methylated in patients with high-risk MDS (refractory anemia with excess blasts [RAEB], RAEB in transformation [RAEB-t], and overt leukemia evolved from MDS; 14/18 [78%]) compared with patients with low-risk MDS (refractory anemia [RA] and refractory anemia with ring sideroblast [RARS]; 1/12 [8%]). Furthermore, methylation status of the p15INK4B gene was progressed with the development of MDS in most patients examined. In contrast, none of the MDS patients showed apparent hypermethylation of the p16INK4A gene. These results suggest that hypermethylation of the p15INK4B gene is involved in the pathogenesis of MDS and is one of the important late events during the development of MDS. Blood, Vol. 90 No. 4 (August 15), 1997: pp. 1403-1409 © 1997 by The American Society of Hematology. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y. Satoh, I. Matsumura, H. Tanaka, S. Ezoe, K. Fukushima, M. Tokunaga, M. Yasumi, H. Shibayama, M. Mizuki, T. Era, et al. AML1/RUNX1 Works as a Negative Regulator of c-Mpl in Hematopoietic Stem Cells J. Biol. Chem., October 31, 2008; 283(44): 30045 - 30056. [Abstract] [Full Text] [PDF] R. B. Klisovic, W. Stock, S. Cataland, M. I. Klisovic, S. Liu, W. Blum, M. Green, O. Odenike, L. Godley, J. V. Burgt, et al. A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia Clin. Cancer Res., April 15, 2008; 14(8): 2444 - 2449. [Abstract] [Full Text] [PDF] J. Markus, M. T. Garin, J. Bies, N. Galili, A. Raza, M. J. Thirman, M. M. Le Beau, J. D. Rowley, P. P. Liu, and L. Wolff Methylation-Independent Silencing of the Tumor Suppressor INK4b (p15) by CBF{beta}-SMMHC in Acute Myelogenous Leukemia with inv(16) Cancer Res., February 1, 2007; 67(3): 992 - 1000. [Abstract] [Full Text] [PDF] S.-H. Kim, J. Rowe, H. Fujii, R. Jones, B. Schmierer, B.-W. Kong, K. Kuchler, D. Foster, D. Ish-Horowicz, and G. Peters Upregulation of chicken p15INK4b at senescence and in the developing brain J. Cell Sci., June 15, 2006; 119(12): 2435 - 2443. [Abstract] [Full Text] [PDF] J. R Kuykendall 5-Azacytidine and Decitabine Monotherapies of Myelodysplastic Disorders Ann. Pharmacother., October 1, 2005; 39(10): 1700 - 1708. [Abstract] [Full Text] [PDF] M. Sullivan, K. Hahn, and J. M. Kolesar Azacitidine: A novel agent for myelodysplastic syndromes Am. J. Health Syst. Pharm., August 1, 2005; 62(15): 1567 - 1573. [Abstract] [Full Text] [PDF] K. N. Bhalla Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993. [Abstract] [Full Text] [PDF] E. Kaminskas, A. Farrell, S. Abraham, A. Baird, L.-S. Hsieh, S.-L. Lee, J. K. Leighton, H. Patel, A. Rahman, R. Sridhara, et al. Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes Clin. Cancer Res., May 15, 2005; 11(10): 3604 - 3608. [Abstract] [Full Text] [PDF] U. Lehmann, I. Berg-Ribbe, L. U. Wingen, K. Brakensiek, T. Becker, J. Klempnauer, B. Schlegelberger, H. Kreipe, and P. Flemming Distinct Methylation Patterns of Benign and Malignant Liver Tumors Revealed by Quantitative Methylation Profiling Clin. Cancer Res., May 15, 2005; 11(10): 3654 - 3660. [Abstract] [Full Text] [PDF] D. P. Steensma and A. F. List Genetic Testing in the Myelodysplastic Syndromes: Molecular Insights Into Hematologic Diversity Mayo Clin. Proc., May 1, 2005; 80(5): 681 - 698. [Abstract] [PDF] E. Kaminskas, A. T. Farrell, Y.-C. Wang, R. Sridhara, and R. Pazdur FDA Drug Approval Summary: Azacitidine (5-azacytidine, VidazaTM) for Injectable Suspension Oncologist, March 1, 2005; 10(3): 176 - 182. [Abstract] [Full Text] [PDF] D. P. Steensma, R. J. Gibbons, and D. R. Higgs Acquired {alpha}-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies Blood, January 15, 2005; 105(2): 443 - 452. [Abstract] [Full Text] [PDF] P. M. Das and R. Singal DNA Methylation and Cancer J. Clin. Oncol., November 15, 2004; 22(22): 4632 - 4642. [Abstract] [Full Text] [PDF] D. H. Christiansen, M. K. Andersen, and J. Pedersen-Bjergaard Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation Blood, September 1, 2004; 104(5): 1474 - 1481. [Abstract] [Full Text] [PDF] Y. Sun, D. Deng, W.-C. You, H. Bai, L. Zhang, J. Zhou, L. Shen, J.-L. Ma, Y.-Q. Xie, and J.-Y. Li Methylation of p16 CpG Islands Associated with Malignant Transformation of Gastric Dysplasia in a Population-Based Study Clin. Cancer Res., August 1, 2004; 10(15): 5087 - 5093. [Abstract] [Full Text] [PDF] J. Gilbert, S. D. Gore, J. G. Herman, and M. A. Carducci The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation Clin. Cancer Res., July 15, 2004; 10(14): 4589 - 4596. [Abstract] [Full Text] [PDF] J. L. Liesveld, C. T. Jordan, and G. L. Phillips II The Hematopoietic Stem Cell in Myelodysplasia Stem Cells, July 1, 2004; 22(4): 590 - 599. [Abstract] [Full Text] [PDF] D. R. Higgs Ham-Wasserman Lecture: Gene Regulation in Hematopoiesis: New Lessons from Thalassemia Hematology, January 1, 2004; 2004(1): 1 - 13. [Abstract] [Full Text] [PDF] H. Hirai Molecular Mechanisms of Myelodysplastic Syndrome Jpn. J. Clin. Oncol., April 1, 2003; 33(4): 153 - 160. [Abstract] [Full Text] [PDF] G. Mufti, A. F. List, S. D. Gore, and A. Y.L. Ho Myelodysplastic Syndrome Hematology, January 1, 2003; 2003(1): 176 - 199. [Abstract] [Full Text] [PDF] L. R. Silverman, E. P. Demakos, B. L. Peterson, A. B. Kornblith, J. C. Holland, R. Odchimar-Reissig, R. M. Stone, D. Nelson, B. L. Powell, C. M. DeCastro, et al. Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B J. Clin. Oncol., May 15, 2002; 20(10): 2429 - 2440. [Abstract] [Full Text] [PDF] A. F. List New Approaches to the Treatment of Myelodysplasia Oncologist, April 1, 2002; 7(90001): 39 - 49. [Abstract] [Full Text] [PDF] C. Nguyen, G. Liang, T. T. Nguyen, D. Tsao-Wei, S. Groshen, M. Lubbert, J.-H. Zhou, W. F. Benedict, and P. A. Jones Susceptibility of Nonpromoter CpG Islands to De Novo Methylation in Normal and Neoplastic Cells J Natl Cancer Inst, October 3, 2001; 93(19): 1465 - 1472. [Abstract] [Full Text] [PDF] L. Teofili, M. Martini, A. Di Mario, S. Rutella, R. Urbano, M. Luongo, G. Leone, and L. M. Larocca Expression of p15ink4b gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors Blood, July 15, 2001; 98(2): 495 - 497. [Abstract] [Full Text] [PDF] E. Hellstrom-Lindberg, C. Willman, A. J. Barrett, and Y. Saunthararajah Achievements in Understanding and Treatment of Myelodysplastic Syndromes Hematology, January 1, 2000; 2000(1): 110 - 132. [Abstract] [Full Text] [PDF] E. E. Cameron, S. B. Baylin, and J. G. Herman p15INK4B CpG Island Methylation in Primary Acute Leukemia Is Heterogeneous and Suggests Density as a Critical Factor for Transcriptional Silencing Blood, October 1, 1999; 94(7): 2445 - 2451. [Abstract] [Full Text] [PDF] R. Singal and G. D. Ginder DNA Methylation Blood, June 15, 1999; 93(12): 4059 - 4070. [Full Text] [PDF] M. L. Heaney and D. W. Golde Myelodysplasia N. Engl. J. Med., May 27, 1999; 340(21): 1649 - 1660. [Full Text] [PDF] T. Uchida, H. Ohashi, T. Kinoshita, H. Saito, R. Taguchi, T. Hotta, and T. Murate Hypermethylation of p15INK4B Gene in a Patient With Acute Myelogenous Leukemia Evolved From Paroxysmal Nocturnal Hemoglobinuria Blood, October 15, 1998; 92(8): 2981 - 2983. [Full Text] [PDF] B. Quesnel, G. Guillerm, R. Vereecque, E. Wattel, C. Preudhomme, F. Bauters, M. Vanrumbeke, and P. Fenaux Methylation of the p15INK4b Gene in Myelodysplastic Syndromes Is Frequent and Acquired During Disease Progression Blood, April 15, 1998; 91(8): 2985 - 2990. [Abstract] [Full Text] [PDF]

	Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020